Gainers
- Enzo Biochem (NYSE:ENZ) stock moved upwards by 12.5% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $76.0 million.
- Avinger (NASDAQ:AVGR) shares rose 10.1% to $0.86. The company's market cap stands at $9.1 million.
- NextGen Healthcare (NASDAQ:NXGN) shares increased by 8.89% to $18.0. The market value of their outstanding shares is at $1.1 billion. The company's, Q1 earnings came out today.
- iSpecimen (NASDAQ:ISPC) stock rose 6.87% to $1.4. The market value of their outstanding shares is at $12.6 million.
- Ra Medical Systems (AMEX:RMED) shares rose 6.56% to $0.72. The company's market cap stands at $4.6 million.
- Plus Therapeutics (NASDAQ:PSTV) stock increased by 6.13% to $2.25. The market value of their outstanding shares is at $5.6 million.
Losers
- NeuroOne Medical Tech (NASDAQ:NMTC) stock fell 27.1% to $1.16 during Monday's after-market session. Trading volume for this security closed at 163.1K, accounting for 102.5% of its average full-day volume over the last 100 days. The company's market cap stands at $20.3 million.
- Medpace Hldgs (NASDAQ:MEDP) stock declined by 8.89% to $225.0. The company's market cap stands at $6.8 billion. As per the news, the Q2 earnings report came out today.
- Etao International Co (NASDAQ:ETAO) shares fell 7.9% to $0.46. Etao International Co's trading volume hit 101.4K shares by close, accounting for 19.4% of its average volume over the last 100 days. The market value of their outstanding shares is at $47.0 million.
- Biodexa Pharmaceuticals (NASDAQ:BDRX) shares declined by 6.21% to $6.05. The market value of their outstanding shares is at $1.4 million.
- NexImmune (NASDAQ:NEXI) stock fell 6.05% to $0.28. The market value of their outstanding shares is at $7.3 million.
- Armata Pharmaceuticals (AMEX:ARMP) shares declined by 5.1% to $1.49. The company's market cap stands at $53.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
